Beckley Psytech Announces Partnership With Empatica in Latest Step of Digital Strategy, Designed to Deliver Personalised Patient Care

Partnership will capture behavioural and physiological signals and predictive biomarkers in Beckley Psytech’s upcoming Phase 2 clinical trials New digital strategy aims to improve patient outcomes and safety by integrating advanced digital tools into the psychedelic treatment journey OXFORD, England–(BUSINESS WIRE)–Beckley Psytech Limited, a private company dedicated to addressing neurological and psychiatric disorders through the … [Read more…]

GenSight Biologics Announces Publication of a Study of the Impact of LHON Disease on the Lives of Patients and Relatives in Journal of Neuro-Ophthalmology

Study is first of its kind to explore the impact of LHON on patients and their relatives in four different countries Study determined that the impact of LHON extends beyond vision-related activity limitations PARIS–(BUSINESS WIRE)–Regulatory News: GenSight Biologics (Euronext: SIGHT, ISIN: FR0013183985, PEA-PME eligible), a biopharma Company focused on developing and commercializing innovative gene therapies … [Read more…]

CORRECTING and REPLACING: NANOBIOTIX Provides First Quarter Operational and Financial Update

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]

Mirum Pharmaceuticals to Participate in Upcoming Investor Conferences

FOSTER CITY, Calif.–(BUSINESS WIRE)–Mirum Pharmaceuticals, Inc. (Nasdaq: MIRM) today announced that it will participate in the following upcoming virtual investor conferences: H.C. Wainwright Global Investment Conference Fireside chat on May 24, 2022 starting at 8:30 a.m. ET Jefferies Healthcare Conference Presentation on June 9, 2022 from 9:00-9:30 a.m. ET Visit the Investors and Media section … [Read more…]

Aptar Named Among the 100 Best Corporate Citizens for 2022

CRYSTAL LAKE, Ill.–(BUSINESS WIRE)–AptarGroup, Inc. (NYSE: ATR), a global leader in drug delivery, consumer product dispensing and active material science solutions and services, announced today that it has been named to 3BL Media’s 100 Best Corporate Citizens ranking for the second year in a row for environmental, social and governance (ESG) transparency and performance. 3BL … [Read more…]

NANOBIOTIX Provides First Quarter Operational and Financial Update

On-track to activate first US clinical trial sites in on-going pivotal phase III global registration study, NANORAY-312, in locally advanced head and neck squamous cell carcinoma (LA-HNSCC) in Q3 2022 Received preliminary feedback from FDA informing development of pivotal Phase III protocol for NBTXR3 in combination with anti-PD-1 therapy, protocol submission planned in Q1 2023 … [Read more…]

DermTech Presents New Research Differentiating Atopic Dermatitis and Psoriasis at the Society for Investigative Dermatology’s Annual Meeting

LA JOLLA, Calif.–(BUSINESS WIRE)–DermTech, Inc. (NASDAQ: DMTK) (“DermTech” or the “Company”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, announced today its presentation at the Society for Investigative Dermatology’s (SID) annual meeting, held from May 18-21, 2022 in Portland, OR. Michael Howell, Ph.D., chief scientific officer at DermTech, presented new research … [Read more…]

Labcorp Launches New Test for People With Skin Cancer

New Assay for Patient Care and Use in Clinical Trials Could Lead to Expanded Treatment Options for Melanoma BURLINGTON, N.C.–(BUSINESS WIRE)–Finding treatment options for skin cancer may become easier with the launch of a new test by Labcorp (NYSE: LH), a leading global life sciences company. The new test measures Lymphocyte-activation gene 3 (LAG-3) expression … [Read more…]

Neurogene Announces New Development Program in Rett Syndrome Utilizing Novel EXACT Technology Platform

Promising preclinical data for NGN-401 presented at 25th Annual Meeting of the American Society of Gene and Cell Therapy (ASGCT) demonstrate significant survival benefit and reduced disease burden in Rett syndrome mouse model Results show Neurogene’s EXACT gene therapy regulates MECP2 gene expression to target levels, avoiding overexpression related toxicity EXACT platform holds potential to … [Read more…]

Adicet Bio to Present at Upcoming Investor Conferences

MENLO PARK, Calif. & BOSTON–(BUSINESS WIRE)–Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing first-in-class allogeneic gamma delta chimeric antigen receptor (CAR) T cell therapies for cancer, today announced that company management will participate in two upcoming investor conferences in May and June. Details of the events are as follows: H.C. … [Read more…]